Data from clinical trials in MM showed that Epacadostat in combination with the anti-CTLA-4 antibody Ipilimumab not only reduced tumor size but also improved disease control rates and PFS in patients [95]. The gene discussed is CTLA4; the disease is Miyoshi myopathy.